Predictors of thromboembolic complications after stent-assisted coiling of acutely ruptured intracranial aneurysms: A retrospective multicenter study

Gaozhi Li †, Haixia Xing ‡, Guohua Mao ‡, Jing Cai ‡, Dianshi Jin ‡, Yujie Tian †, Xiaohua Zhang † and Bing Zhao † *

† Department of Neurosurgery, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China; ‡ Department of Pathology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai, China; * Department of Neurosurgery, The Second Affiliated Hospital of Nanchang University, Nanchang, China; ‡ Department of Neurosurgery, Linyi People’s Hospital, Linyi, China; ‡ Department of Neurosurgery, Dalian Central Hospital, Dalian, China

Background: Stent-assisted coiling (SAC) has been reported to safely and effectively treat wide-necked unruptured intracranial aneurysms. However, SAC of acutely ruptured aneurysms is controversial because of perioperative thromboembolic complications. We aimed to investigate the predictors of the thromboembolic complications after SAC of acutely ruptured aneurysms.

Methods: We performed a retrospective multicenter analysis of 110 consecutive patients with ruptured intracranial aneurysms treated with SAC within 72h of the onset of subarachnoid hemorrhage. Thromboembolic complications were defined as any angiographic filling defects at the aneurysms base or the distal artery during the stent treatment and the new onset of symptomatic ischemia and a new hypo-density in a vascular distribution confirmed by CT scan within 24h of treatment. These patients were grouped into patients with thromboembolic complications and those without thromboembolic complications. A multivariate logistic regression analysis was performed to identify predictors of thromboembolic complications.

Results: One hundred and one patients with 101 ruptured aneurysms were included in this study. 9 (8.9%) patients experienced thromboembolic complications. Patients with thromboembolic complications had a higher rate of unfavorable outcomes at discharge (P < 0.001) and at the last follow-up (p = 0.017). Of these patients, four patients presented with intraprocedural thrombus formation, and 5 experienced postprocedural ischemia. There was a trend toward thromboembolic complications in patients with a higher Fisher grade (p = 0.076) and those treated with intravenous tirofiban (p = 0.052). Patients with thromboembolic complications more often presented with poor grade clinical conditions (p = 0.005) and aneurysms with a large dome to neck ratio (p = 0.031). In the multivariate analysis, a worse World
Conclusion: Patients with thromboembolic complications are more likely to have an unfavorable outcome. A worse clinical condition before the treatment and a larger dome to neck ratio were independent predictors of thromboembolic complications after SAC of acutely ruptured intracranial aneurysms.

KEYWORDS
intracranial aneurysm, ruptured aneurysm, endovascular treatment, stent-assisted coiling, thromboembolic complication

Introduction

Aneurysmal subarachnoid hemorrhage (aSAH) is a fatal hemorrhagic stroke with a 30-day mortality rate of 45%, and about 30% of survivors have moderate to severe disability (1). Surgical clipping and endovascular treatment are essential treatment modalities to prevent rebleeding after a ruptured aneurysm. Endovascular treatment has a lower incidence of unfavorable outcomes than surgical clipping and has become an alternative treatment for ruptured aneurysms (2).

With the development of neurointerventional technologies, stent-assisted coiling (SAC) has been used to treat wide-necked unruptured intracranial aneurysms with a relatively low recurrence rate at follow-up angiography. SAC of ruptured aneurysms may be feasible, safe, and effective in current studies (3, 4). However, periprocedural complications more often occur in SAC of ruptured aneurysms than unruptured aneurysms or single coiling of ruptured aneurysms (3–6). Stents usually require dual antiplatelet therapy concerning hemorrhage, especially with bleeding from the external ventricular drainage or placement of a ventriculoperitoneal shunt (2, 7). Moreover, the thrombotic events are the most common complications after SAC of ruptured aneurysms and are associated with increased mortality (6, 8–10). Therefore, the SAC of acutely ruptured aneurysms is still controversial (2, 7). Identifying predictors of thromboembolic complications is vital for patients’ safe treatment.

The Low-profile Visualized Intraluminal Support (LVIS) device is self-expanding nickel titanium, single-wire braid, retrievable, closed-cell microstent (8). The pivotal US LVIS trial results have shown that the LVIS stents allow safe and highly effective coiling of wide-necked aneurysms (11). However, the LVIS stents with higher metal coverage seem to cause more common thromboembolic complications than others, including Neuroform and Enterprise stents (9, 12). In this study, we performed a retrospective multicenter analysis of SAC of ruptured aneurysms within 72 h of the onset of subarachnoid hemorrhage with LVIS stents. We aimed to investigate the predictors of thromboembolic complications after SAC of acutely ruptured aneurysms.

Methods

Study design and patients

The institutional review board approved this study, and the informed consent was waived. This retrospective multicenter study focused on patients with acutely ruptured aneurysms treated with LVIS stents (13). One hundred and ten consecutive patients with ruptured aneurysms performed SAC within 72 h of the onset between January 2017 to December 2017. Four centers were tertiary hospitals with more than 150 intracranial aneurysms each year. We collected clinical characteristics, including demographic information, medical history, personal history, World Federation of Neurosurgical Societies (WFNS) grade before the treatment, Fisher grade, clinical treatment reports, aneurysm characteristics, periprocedural complications, and clinical outcomes.

Endovascular treatment protocol

Endovascular treatment was considered in patients with ruptured aneurysms whose characteristics were suitable for coiling or clipping, or those with posterior circulation aneurysms. SAC was used for wide-necked aneurysms (neck size ≥4 mm or dome to neck ratio ≤2). All ruptured aneurysms were treated by LVIS (Microvention/Terumo, Tustin, CA). These procedures were performed under general anesthesia. A 50–75 IU/kg bolus of heparin was used for heparinization. The stent was manipulated by semi-jailing technology of partially deploying to cover the aneurysm neck. External
ventricular drainage (EVD) was often considered in patients with acute hydrocephalus or severe intraventricular hemorrhage (IVH) after the treatment. Patients were transferred to the neurosurgical intensive care unit (NICU) and treated with standard management for vasospasm.

**Antiplatelet management**

There was no standard protocol for antiplatelet therapy, and the regimens were prescribed according to institutional standards in four medical centers. Two different protocols were used in this study. One is a loading dose of 300 mg clopidogrel and 300 mg aspirin administered through a nasogastric tube or rectally 2 h before the stent deployment. The other is a loading dose of tirofiban (8–10 ug/kg) infused intravenously during the stent deployment. Tirofiban was maintained at 0.10 ug/kg/min for at least 12 h after the procedure. If thromboembolic complications occurred, 5–10 ml of tirofiban were infused through the microcatheter, and immediate angiography was checked every 5–10 min. Dual antiplatelet therapy (100 mg of aspirin and 75 mg of clopidogrel) was prescribed daily. The platelet function testing was not routinely measured.

**Thromboembolic complications**

**definition**

The primary outcome was the thromboembolic complication. The thromboembolic complications were defined as angiographic filling defects at the aneurysms base or the distal artery during the stent treatment and the new onset of symptomatic ischemia and a new hypo-density in parent and distal arteries distribution in the first 24 h after the procedure (13). Angiograms and CT scans were reviewed by both independent interventional neuroradiologist and neurosurgeon who were not involved in the treatment. These patients were grouped into patients with thromboembolic complications and those without thromboembolic complications.

**Clinical outcome measurement**

Clinical outcomes at discharge and the last follow-up were measured using a modified Rankin Scale (mRS). The favorable outcome was defined as a mRS of 0–2. The mean time of follow-up was 15.9 ± 10.4 months.

**TABLE 1** Baseline characteristics between patients with thromboembolic complications and those without complications.

| Variables                  | Thromboembolic complications (n = 9) | Without thromboembolic complications (n = 92) | P-value |
|----------------------------|--------------------------------------|-----------------------------------------------|---------|
| Age (years, ± SD)          | 61.8 (10.4)                          | 58.0 (10.4)                                   | 0.296   |
| No. (male/female)          | 9 (1/8)                              | 92 (32/60)                                    | 0.180   |
| Current smoking (%)        | 0 (0)                                | 21 (22.8)                                     | 0.998   |
| Hypertension (%)           | 6 (66.7)                             | 48 (52.2)                                     | 0.411   |
| WFNS grade (%)             |                                      |                                               | 0.005   |
| Grade I-III                | 5 (55.6)                             | 84 (91.3)                                     |         |
| Grade IV-V                 | 4 (44.4)                             | 8 (8.7)                                       |         |
| Fisher grade (%)           |                                      |                                               | 0.076   |
| Grade I-II                 | 4 (44.4)                             | 68 (73.9)                                     |         |
| Grade III-IV               | 5 (55.6)                             | 24 (26.1)                                     |         |
| Angiographic vasospasm (%) | 2 (22.2)                             | 20 (21.7)                                     | 0.973   |
| Multiple aneurysms (%)     | 2 (22.2)                             | 14 (15.2)                                     | 0.586   |
| **Aneurysm location (%)**  |                                      |                                               |         |
| ACA-ACoA                   | 1 (11.1)                             | 24 (26.1)                                     | 0.340   |
| PCoA-ICA                   | 6 (66.7)                             | 56 (60.9)                                     | 0.734   |
| MCA                        | 2 (22.2)                             | 6 (6.5)                                       | 0.120   |
| Posterior circulation      | 0 (0)                                | 6 (6.5)                                       | 0.999   |
| Aneurysm size (mm, ± SD)   | 5.8 (2.6)                            | 4.5 (2.7)                                     | 0.185   |
| Neck size (mm, ± SD)       | 3.8 (1.4)                            | 3.7 (1.6)                                     | 0.814   |
| Dome to neck ratio         | 1.6 (0.5)                            | 1.2 (0.4)                                     | 0.031   |
| **Antiplatelet regimens (%)** |                                    |                                               |         |
| Aspirin and clopidogrel    | 5 (55.6)                             | 77 (83.7)                                     | 0.052   |
| Tirofiban                  | 4 (44.4)                             | 15 (16.3)                                     | 0.052   |

WFNS, World Federation of Neurological Society; ACA, anterior cerebral artery; ACoA, anterior communicating artery; PCoA, posterior communicating artery; ICA, internal carotid artery; MCA, middle cerebral artery.
TABLE 2 Clinical outcomes between patients with thromboembolic complications and those without complications.

| Clinical outcomes | Thromboembolic complications (n = 9) | Without thromboembolic complications (n = 92) | P-value |
|------------------|-------------------------------------|---------------------------------------------|---------|
| mRS at discharge  |                                     |                                             |         |
| mRS0-2           | 3 (33.3%)                           | 81 (88%)                                    | 0.001   |
| mRS3-5           | 6 (66.7%)                           | 9 (9.8%)                                    | <0.001  |
| mRS6             | 0 (0)                               | 2 (2.2%)                                    | 0.999   |
| mRS at follow-up |                                     |                                             |         |
| mRS0-2           | 6 (66.7%)                           | 83 (91.2%)                                  | 0.039   |
| mRS3-5           | 3 (33.3%)                           | 6 (6.6%)                                    | 0.017   |
| mRS6             | 0 (0)                               | 2 (2.2%)                                    | 0.999   |

mRS, modified Rankin Scale.

Statistical analysis

Statistical analysis was performed with SPSS 22.0 (IBM SPSS; Armonk, NY, US). Continuous data were presented as mean ± standard deviations, and categorical variables were given as frequency (percentage). The Chi-square test and Fisher’s precision test were used for categorical variables. The t-test and Wilcoxon’s rank-sum test were used for continuous variables. We compared demographic information, clinical characteristics, and outcomes between patients with thromboembolic complications and those without thromboembolic complications group. Univariate and multivariate logistic regression analyses were performed to identify the predictors of thromboembolic complications. Variables with a p-value < 0.1 in univariate analysis were entered into the multivariate analysis using the backward method. Odds ratio (OR) and 95% confidence interval (CI) were calculated. A p-value < 0.05 was considered to be statistically significant.

Results

Baseline characteristics

Out of the 110 patients, 101 patients with 101 ruptured aneurysms were included in this study. Three patients with carotid artery blood blister aneurysms, 4 with dissection aneurysms, and 2 with multiple aneurysms were excluded. The mean time of SAC of aneurysms was 31.6 ± 18.8 h of subarachnoid hemorrhage. 49 (48.5%) patients were treated within 24 h. 9 (8.9%) patients experienced thromboembolic complications. Of these patients, four patients experienced intraprocedural thrombus formation, and 5 experienced ischemia after treatment. Baseline characteristics between patients with thromboembolic complications and those without thromboembolic complications groups are presented in Table 1.

Clinical outcomes

Clinical outcomes at discharge and follow-up are presented in Table 2. The last follow-up was available for 100 (99%) patients. 84 (83.2%) patients achieved a favorable outcome (mRS 0–2) at discharge. Patients with thromboembolic complications more often had a higher rate of unfavorable outcomes at discharge (P < 0.001) and at the last follow-up (p = 0.017). There was no statistically significant difference in the mortality rate between the two groups (p = 0.999).

Predictors of thromboembolic complications

Results of the univariate and multivariate analyses of predictors of thromboembolic complications are presented in Table 3. There was a trend toward thromboembolic complications in patients with a higher Fisher grade (p = 0.076) and treated with intravenous tirofiban (p = 0.052). Patients with thromboembolic complications presented with a WFNS grade of IV-V (p = 0.005) and a larger dome to neck ratio (p = 0.031). In the multivariate analysis, poor WFNS grade (OR = 8.241; 95% CI 1.686–40.292; p = 0.009) and a larger dome to neck ratio (OR = 5.385; 95% CI 1.023–28.337; p = 0.047) were independently associated with the presence of thromboembolic complications.

Discussion

We performed a retrospective multicenter analysis of patients with acutely ruptured intracranial aneurysms treated with stents. We found that patients with thromboembolic
complications more often had an unfavorable outcome. There was a trend toward thromboembolic complications in patients with a higher Fisher grade and those treated with intravenous tirofiban. A worse clinical condition and a larger dome to neck ratio were independently associated with the presence of thromboembolic complications. These findings suggest that selected patients with a good clinical grade and a small dome to neck ratio could be safely treated with SAC with a lower risk of thromboembolic complications.

We found that thromboembolic complications occurred in 8.9% of patients treated with SAC within 72 h of hemorrhage. This complication is not rare in the treatment of acutely ruptured aneurysms. Our finding is similar to previous studies that showed the incidence of thromboembolic complications was 7.8–15% after SAC of ruptured intracranial aneurysms (14–17). Bat et al. (18) systematically reviewed the literature on SAC of acutely ruptured aneurysms in 1,582 patients and found that the overall rate of thromboembolic complications was 9.1% (95% CI: 6.0–12.7%; I² = 72.8%). There was a high rate of thromboembolic complications, probably because of insufficient coverage of antiplatelet therapy or antiplatelet resistance (19). Recently, Xue et al. (20) reported that ischemic procedure-related complications occurred in 3 (7.5%) of 40 patients with 40 ruptured middle cerebral artery aneurysms with glycoprotein IIb/IIIa inhibitor for the LVIS stents treatment of ruptured aneurysms. Meanwhile, previous studies have shown that thromboembolic complications increase procedural disability (6, 8, 9). We also found unfavorable clinical outcomes more often in patients with thromboembolic complications.

We found that a poor-grade clinical condition (WFNS grade of IV or V) was an independent predictor of thromboembolic complications. Imamura et al. (6) also reported that a poor grade condition on admission was a risk factor for ischemic complication during endovascular embolization of ruptured aneurysms. An elevated D-dimer concentration was observed in most patients with ruptured aneurysms, especially in patients with a poor-grade SAH. Elevated D-dimer levels on admission independently had a higher risk of thromboembolic events (21).

We found that ruptured aneurysms with a large dome to neck ratio were associated with increased thromboembolic complications. Liu et al. (22) also reported periprocedural thromboembolic complications were more likely to occur in ruptured aneurysms with a smaller dome to neck ratio. However, there was no statistically significant difference. Our previous study regarding predicting inprocedural complications during coiling of ruptured anterior communication artery aneurysms showed that aneurysm neck size and parent vessel angle were independent predictors of thrombus formation (10). The definitive relationship between aneurysm morphology and periprocedural complication is still unknown.

We found no significant difference in thromboembolic complications in both antiplatelet therapy regimens. There was a trend toward thromboembolic complications in patients with intravenous tirofiban. Kim et al. (23) conducted a retrospective analysis of patients who underwent SAC of ruptured aneurysms using intravenous tirofiban instead of loading doses of dual antiplatelet agents. They found that tirofiban may be an effective and safe alternative with a low risk of thromboembolic complications. However, there is no standardized antiplatelet management for SAC of ruptured aneurysms, and the DELPHI consensus statement prefers a dual-antiplatelet regimen with aspirin and a glycoprotein IIb/IIIa inhibitor (24).

There is a paucity of data on antiplatelet management for SAC of acutely ruptured aneurysms, and the relationship between antiplatelet therapy regimens and thrombotic complications requires further study. P2Y12 reaction test could predict thrombotic complications, but its value is uncertain. The P2Y12 test to guide clopidogrel therapy did not decrease the incidence of thromboembolism complications (25). Kim et al. (26) found that high antiplatelet drug resistance was associated with postprocedural infarction after coiling for unruptured aneurysms. Li et al. (27) conducted a retrospective analysis of patients who received modified antiplatelet therapy using thromboelastography (TEG) after SAC of ruptured aneurysms, and they found no significant difference in the rates of thromboembolic events between individualized antiplatelet therapy with TEG parameters and standard dual antiplatelet therapy without TEG test groups. Their tests were performed on the 3rd day after treatment of ruptured aneurysms (27). In our study, nearly half of the patients were treated within 24 h, and the time-costing test is challenging for treating acutely ruptured aneurysms.

Our study has several limitations. First, this was a retrospective multicenter study. Antiplatelet regimens vary widely. Thromboelastogram or drug sensitivity gene tests for platelet were not routinely examined in the emergency department in these centers. Second, we included symptomatic ischemia. The incidence of asymptomatic ischemia may be underestimated because diffusion-weighted imaging was not routinely performed within 24 h. Third, aneurysm morphology may affect the incidence of thromboembolic complications. We did not yet identify the exact procedure reasons, including vasospasm after stimulation during the operation of the catheter and guide wire or thrombosis in the catheter due to insufficient irrigation water during the procedure in this retrospective study. Besides, all aneurysms were treated with LVIS stents. LVIS seems to cause more common procedural-related thrombotic events than the other stents (9, 12). There is variability in choice and techniques of stent type. Whether this finding is generalized to other stents still requires further study. Nevertheless, these data represent the stent treatment of acutely
ruptured aneurysms and may be more helpful in guiding the treatment decision.

Conclusion

We conducted a multicenter cohort of patients with acutely ruptured intracranial aneurysms treated with SAC. Patients with thromboembolic complications more often had an unfavorable outcome and presented with a poor WFNS grade. Selected patients with a good clinical grade and a small aneurysm dome to neck ratio could be safely treated with SAC with a lower thromboembolic complication rate.

Data availability statement

The original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.

Ethics statement

The studies involving human participants were reviewed and approved by the Institutional Review Board of Renji Hospital, Shanghai Jiao Tong University School of Medicine. Written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements.

Author contributions

GL and HX wrote the first manuscript. GM, JC, DJ, YT, and BZ were involved in the acquisition and analysis of the data. HX and BZ contributed to the statistical analysis. XZ and BZ were involved in the conceptualization of the study. All authors were involved in data interpretation and approved the final manuscript.

Funding

This work was supported by Shanghai Science and Technology Project (21Y11906200), National Facility for Translational Medicine (Shanghai) TMSK-2021-147.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. Bittman JL, Song JK, Newell DW. Cerebral aneurysms. N Engl J Med. (2006) 355:928–39. doi: 10.1056/NEJMra052760
2. Connolly Jr ES, Rabinstein AA, Carhuapoma JR, Derdeyn CP, Dion J, Higashida RT, et al. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a guideline for healthcare professionals from the American heart association/american stroke association. Stroke. (2012) 43:1711–37. doi: 10.1161/STR.0b013e3182587839
3. Bechan RS. Stent-assisted coil embolization of intracranial aneurysms: complications in acutely ruptured versus unruptured aneurysms. AJNR Am J Neuroradiol. (2016) 37:502–7. doi: 10.3174/ajnr.A4542
4. Yang H. Comparison of stent-assisted coiling vs coiling alone in 563 intracranial aneurysms: safety and efficacy at a high-volume center. Neurosurgery. (2015) 77:241–7, discussion 247. doi: 10.1227/NEU.0000000000000765
5. Fan L, Tan X, Xiong Y, Zheng K, Li Z, Liu D, et al. Stent-assisted coiling versus coiling alone of ruptured anterior communicating artery aneurysms: a single-center experience. Clin Neurol Neurosurg. (2016) 144:96–100. doi: 10.1016/j.clineuro.2016.03.020
6. Imamura H, Sakai N, Satow T, Ibara K, Group J-NS. Factors related to adverse events during endovascular coil embolization for ruptured cerebral aneurysms. J Neurosurg (2020) 120:605–9. doi: 10.1093/jnci/djz155
7. Tawk RG, Hasan TD, D’Souza CE, Peel JB, Freeman WD. Diagnosis and treatment of unruptured intracranial aneurysms and aneurysmal subarachnoid hemorrhage. Mayo Clin Proc. (2021) 96:1970–2000. doi: 10.1016/j.mayocp.2021.01.005
8. Zhang X, Zhong J, Gao H, Xu F, Bambakidis NC. Endovascular treatment of intracranial aneurysms with the LVIS device: a systematic review. J Neurointerv Surg. (2017) 9:553–7. doi: 10.1136/neurintsurg-2016-012403
9. Wang J, Vargas I, Spotta A, Chaudry I, Turner RD, Lena J, et al. Stent-assisted coiling of cerebral aneurysms: a single-center clinical and angiographic analysis. J Neurointerv Surg. (2018) 10:687–92. doi: 10.1136/neurintsurg-2017-013272
10. Fan L, Lin B, Xu T, Xia N, Shao X, Tan X, et al. Predicting intraprocedural rupture and thrombus formation during coiling of ruptured anterior communicating artery aneurysms. J Neurointerv Surg. (2017) 9:370–5. doi: 10.1136/neurintsurg-2016-012335
11. Fiorella D, Boulou S, Turk AS, Siddiqui AH, Arthur AS, Diaz O, et al. The safety and effectiveness of the LVIS stent system for the treatment of wide-necked cerebral aneurysms: final results of the pivotal US LVIS trial. J Neurointerv Surg. (2019) 11:357–61. doi: 10.1136/neurintsurg-2018-014309
12. Mokin M, Primiani CT, Ren Z, Piper K, Fiorella DJ, Rai AT, et al. Stent-assisted coiling of cerebral aneurysms: multi-center analysis of radiographic and clinical outcomes in 659 patients. J Neurointerv Surg. (2020) 12:289–97. doi: 10.1136/neurintsurg-2019-015182
13. Wang X, Xing H, Cai J, Jin D, Chen Y, Cui Y, et al. The safety and efficacy of the LVIS stent for the treatment of ruptured intracranial aneurysms.
within 24 hours: a multicenter retrospective study. Clin Neurol Neurosurg. (2020) 197:106117. doi: 10.1016/j.clineuro.2020.106117

14. Muto M, Giurazza F, Ambrosiano G, Vassallo F, Briganti F, Tecame M, et al. Stent-assisted coiling in ruptured cerebral aneurysms: multi-center experience in acute phase. La Radiol Med. (2017) 122:43–52. doi: 10.1080/011547-016-0686-6

15. Liu Y, Wang F, Wang M, Zhang G. Comparison of stent-assisted coil placement and coiling only for the treatment of ruptured intracranial aneurysms. Med Sci Monit. (2017) 23:5697–704. doi: 10.12659/MSM.905107

16. Yang P, Zhao K, Zhou Y, Zhao R, Zhang L, Zhan W, et al. Stent-assisted coil placement for the treatment of 211 acutely ruptured wide-necked intracranial aneurysms: a single-center 11-year experience. Radiology. (2015) 276:545–52. doi: 10.1148/radiol.2015140974

17. Chung J, Lim YC, Suh SH, Shim YS, Kim YB, Joo J-Y, et al. Stent-assisted coil embolization of ruptured wide-necked aneurysms in the acute period: incidence of and risk factors for peri-procedural complications. J Neurosurg. (2014) 121:4–11. doi: 10.3171/2014.4.JNS131662

18. Bsat S, Bsat A, Tamim H, Chanbour H, Alomari SO, Houshiemy MNE, et al. Safety of stent-assisted coiling for the treatment of wide-necked ruptured aneurysm: a systematic literature review and meta-analysis of prevalence. Int Neuroradiol. (2020) 26:547–56. doi: 10.1177/1591019920945059

19. Oxley TJ, Dowling RJ, Mitchell PJ, Davis S, Yan B. Antiplatelet resistance and thromboembolic complications in neurointerventional procedures. Front Neurol. (2011) 2:83. doi: 10.3389/fneur.2011.00083

20. Xue G, Zhou Y, Liu P, Zuo Q, Yang P, Fang Y, et al. Endovascular treatment of ruptured middle cerebral artery aneurysms with a low-profile visualized intraluminal support device. Front Neurol. (2020) 11:631745. doi: 10.3389/fneur.2020.631745

21. Fukuda H, Handa A, Koyanagi M, Lo B, Yamagata S. Association of plasma D-dimer level with thromboembolic events after endovascular coil treatment of ruptured cerebral aneurysms. J Neurosurg. (2018) 2018:1–8. doi: 10.3171/2017.7.JNS171129

22. Liu P, Lv X, Li Y, Lv M. Stent-assisted coiling of ruptured wide-necked intracranial aneurysms: a single-center experience of 218 consecutive patients. Neuroradiology. (2016) 2016(Suppl. 64):S70–7. doi: 10.1007/9026-3886.178045

23. Kim S, Choi JH, Kang M, Cha JK, Huh JT. Safety and efficacy of intravenous tirofiban as antiplatelet premedication for stent-assisted coiling in acutely ruptured intracranial aneurysms. Am J Neuroradiol. (2016) 37:508–14. doi: 10.3174/ajnr.A4551

24. Ospel JM, Brouwer P, Dorn F, Arthur A, Jensen ME, Nogueira R, et al. Antiplatelet management for stent-assisted coiling and flow diversion of ruptured intracranial aneurysms: a delphi consensus statement. AJNR Am J Neuroradiol. (2020) 41:1856–62. doi: 10.3174/ajnr.A6814

25. Wong P, Tesoro F, Aletich V, Alaraj A. Accumetrics-based clopidogrel dosing in endovascular neurosurgery. Neurorad. (2015) 37:998–1005. doi: 10.1179/1743132815Y.0000000084

26. Kim MS, Jo KL, Yeon JY, Kim JS, Kim KH, Jeon P, et al. Association between post-procedural infarction and antiplatelet drug resistance after coiling for unruptured intracranial aneurysms. AJNR Am J Neuroradiol. (2016) 37:1099–105. doi: 10.3174/ajnr.A4777

27. Li Y, Zhang X, Guo Z, Zhu J, Xu R, He Z, et al. Standard vs. modified antiplatelet therapy based on thromboelastography with platelet mapping for preventing bleeding events in patients undergoing stent-assisted coil for a ruptured intracranial aneurysm. Front Neurol. (2020) 11:615829. doi: 10.3389/fneur.2020.615829